These adaptation mechanisms may serve as potential target for glioma therapy and suggest that β-oxidation inhibitors and probably lysosomal inhibitors (Figure 5A) may potentiate the effect of PARP inhibition in glioblastoma, and contribute to increased life expectancy in the patients of this malignant disease. This evidence concerns the gene PARP1 and glioblastoma.